^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + BGB659 (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition
Excerpt:
...the combination of BGB659 with cetuximab led to significantly better growth inhibition in vitro than BGB659 alone in both HT-29_NRAS and Vaco432_NRAS cells...BGB659/cetuximab treatment was not only effective in the RAS amplification driven vemurafenib resistant CRC cells, but also in other models of resistance.
DOI:
10.1158/0008-5472.CAN-17-0768
